Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 4:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HER2 Negative Breast Neoplasms Clear all
Active, not recruiting Phase 2 Interventional Results available

A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer

NCT02747004
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Abemaciclib, Tamoxifen, Prophylactic Loperamide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
5
States / cities
Tucson, Arizona • Lebanon, New Hampshire • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jul 23, 2026, 4:33 PM EDT
Active, not recruiting Phase 2 Interventional

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

NCT05150652
View directory record Official record
Conditions
Breast Cancer, HER2-negative Breast Cancer, Node-negative Breast Cancer, Breast Carcinoma
Interventions
Anastrozole 1mg, Letrozole 2.5mg, Exemestane 25 mg, Tamoxifen
Drug
Lead sponsor
Irada Ibrahim-zada
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jul 23, 2026, 4:33 PM EDT
Not listed Phase 2 Interventional

Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer

NCT05025735
View directory record Official record
Conditions
Metastatic Breast Cancer, HER2-negative Breast Cancer
Interventions
Dapagliflozin 10Mg Tab
Drug
Lead sponsor
Saint Luke's Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Jul 23, 2026, 4:33 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

NCT07062965
View directory record Official record
Conditions
Breast Cancer
Interventions
PF-07248144, Fulvestrant, Everolimus, Exemestane
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
102
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 23, 2026, 4:33 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

NCT05262400
View directory record Official record
Conditions
Breast Cancer, Solid Tumors
Interventions
PF-07220060 + PF-07104091 combination dose escalation, PF-07104091 + PF-07220060 + fulvestrant dose expansion, PF-07104091 + PF-07220060 + letrozole dose expansion
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
12
States / cities
Los Angeles, California • Santa Monica, California • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2024 · Synced Jul 23, 2026, 4:33 PM EDT
Completed No phase listed Observational

Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer

NCT06040593
View directory record Official record
Conditions
Hormone-receptor-positive Breast Cancer, HER2-low Breast Cancer, HER2-negative Breast Cancer
Interventions
No drug
Other
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
927 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 25, 2024 · Synced Jul 23, 2026, 4:33 PM EDT
Recruiting Phase 1 Interventional

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

NCT06562192
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer, Colorectal Cancer
Interventions
[68Ga]Ga-NNS309, [177Lu]Lu-NNS309
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 23, 2026, 4:33 PM EDT
Terminated Phase 1 Interventional Results available

A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer

NCT02561832
View directory record Official record
Conditions
Breast Cancer
Interventions
Olaparib, Carboplatin, Anthracycline, Cyclophosphamide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
New York, New York • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Jul 23, 2026, 4:33 PM EDT
Not listed Phase 2 Interventional

Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast

NCT03812393
View directory record Official record
Conditions
Triple Negative Breast Cancer, Early-stage Breast Cancer, HER2-positive Breast Cancer
Interventions
Neratinib
Drug
Lead sponsor
West Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 17, 2023 · Synced Jul 23, 2026, 4:33 PM EDT
Completed Phase 2 Interventional

Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer

NCT00472693
View directory record Official record
Conditions
Breast Cancer
Interventions
Bevacizumab, Abraxane
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Jul 23, 2026, 4:33 PM EDT
Not yet recruiting No phase listed Observational

Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases

NCT07619534
View directory record Official record
Conditions
Breast Cancer, Breast Carcinoma, Cancer of the Breast, Malignant Neoplasm of Breast
Interventions
Arm 1
Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Jul 23, 2026, 4:33 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

NCT06993844
View directory record Official record
Conditions
Advanced Solid Tumors, Advanced Breast Cancer
Interventions
ETX-636 dose escalation, ETX-636 dose escalation in combination with fulvestrant, ETX-636 dose expansion in combination with fulvestrant
Drug
Lead sponsor
Ensem Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
Newport Beach, California • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jul 23, 2026, 4:33 PM EDT
Not listed Phase 2 Interventional

Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer

NCT00491816
View directory record Official record
Conditions
Breast Cancer
Interventions
Erlotinib with neoadjuvant chemotherapy
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Jul 23, 2026, 4:33 PM EDT
Recruiting No phase listed Observational

DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients

NCT06388122
View directory record Official record
Conditions
HER2-negative Breast Cancer, Hormone-receptor-positive Breast Cancer, Metastatic Breast Cancer, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, HER2 Negative Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma
Interventions
Biospecimen Collection
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jul 23, 2026, 4:33 PM EDT
Recruiting Not applicable Interventional

Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer

NCT06106477
View directory record Official record
Conditions
Breast Cancer
Interventions
Intermittent Fasting
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Jul 23, 2026, 4:33 PM EDT
Active, not recruiting Phase 3 Interventional

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

NCT06760637
View directory record Official record
Conditions
Breast Cancer
Interventions
PF-07220060, letrozole, abemaciclib, palbociclib, ribociclib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2037
U.S. locations
218
States / cities
Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 135 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 23, 2026, 4:33 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of AVZO-021 in Patients With Advanced Solid Tumors

NCT05867251
View directory record Official record
Conditions
Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Endometrial Cancer, TNBC - Triple-Negative Breast Cancer
Interventions
AVZO-021, Palbociclib, Fulvestrant, Letrozole, Ribociclib, Abemaciclib, Carboplatin, Sacituzumab Govitecan-hziy
Drug
Lead sponsor
Avenzo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
11
States / cities
New Haven, Connecticut • Sarasota, Florida • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Jul 23, 2026, 4:33 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer

NCT02107703
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Abemaciclib, Fulvestrant, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
43
States / cities
Jonesboro, Arkansas • Springdale, Arkansas • La Jolla, California + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Jul 23, 2026, 4:33 PM EDT
Recruiting Phase 2 Interventional

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

NCT05020860
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasm, Breast Cancer Female, Breast Cancer Invasive, Breast Cancer Stage II, Breast Cancer Stage III, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Neoplasms, Estrogen Receptor-positive Breast Cancer
Interventions
Paclitaxel, Carboplatin, Trastuzumab, Pertuzumab, Doxorubicin, Cyclophosphamide, Pembrolizumab, Pertuzumab/Trastuzumab/Hyaluronidase-zzxf
Drug
Lead sponsor
Baylor Breast Care Center
Other
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Jul 23, 2026, 4:33 PM EDT
Terminated Phase 3 Interventional Results available

S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer

NCT02137837
View directory record Official record
Conditions
Breast Cancer
Interventions
Fulvestrant, Anastrozole, Everolimus, Placebo - Anastrozole, Placebo - Everolimus
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
223
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 150 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Jul 23, 2026, 4:33 PM EDT
Completed Phase 3 Interventional

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

NCT00005970
View directory record Official record
Conditions
Breast Adenocarcinoma, HER2 Positive Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7
Interventions
Aromatase Inhibition Therapy, Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Tamoxifen Citrate, Trastuzumab
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
3,436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
154
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 119 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Jul 23, 2026, 4:33 PM EDT
Active, not recruiting Phase 3 Interventional Results available

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

NCT01674140
View directory record Official record
Conditions
Breast Cancer
Interventions
anastrozole, everolimus, exemestane, goserelin acetate, letrozole, leuprolide acetate, tamoxifen citrate, placebo
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
1,939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
1455
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 887 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jul 23, 2026, 4:33 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies

NCT04172597
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Solid Tumor, Glioblastome Multiforme
Interventions
Poziotinib Hydrochloride, Loperamide
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Jul 23, 2026, 4:33 PM EDT
Completed No phase listed Observational Results available

Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

NCT06086340
View directory record Official record
Conditions
Breast Cancer
Interventions
Palbociclib, Aromatase Inhibitor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
65 Years and older
Enrollment
779 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Jul 23, 2026, 4:33 PM EDT